Widening the Lens On Parkinson's Disease

I created this for an old activist friend who was wondering what comes next when Parkinson's meds stop working. He had never heard of nutritional or environmental medicine. Hadn't thought about mitochondria since high school biology. Pretty sure he thinks talk of heavy metals or pesticides is either woo-woo or MAHA crazy talk. I realize this is a huge conceptual leap. It probably took me ten years to adjust the way I saw and thought about medicine and health, and I wasn't in the middle of a health crisis needing to believe in my specialist. But I hope he takes it. Or that it helps someone else. Listening to Alan Alda interview yesterday didn't give me much hope. If this ostensibly super educated/worldly (and yes, privileged) guy still accepts a label for his symptoms and doesn't think to ask basic questions about what might be going on inside his body, how can we expect anyone else to?

1. The Standard Picture (and Its Limits)

The conventional understanding of Parkinson's disease centers on the loss of dopamine-producing neurons in a brain region called the substantia nigra. This neuronal loss causes the hallmark motor symptoms: tremor, rigidity, slowness of movement. The standard treatment, levodopa (L-DOPA), replaces the missing dopamine. It works, often for years, and remains the most effective symptomatic therapy available.

But two things have become increasingly clear:

First, by the time motor symptoms are diagnosed, substantial neuronal loss has already occurred. The disease process has been underway for years, possibly decades. Second, Parkinson's is not a brain-only disease. It involves the gut, the immune system, cellular energy production (mitochondria), and systemic inflammation in ways that the standard dopamine-replacement model does not address.

2. The Gut-Brain Connection: Not Metaphorical, Anatomical

2a. Constipation as a Canary

One of the most striking epidemiological findings in PD research is that constipation often precedes the onset of motor symptoms by 10 to 20 years. Clinical reports show that patients with PD may develop constipation two decades before motor symptoms appear, making it one of the earliest recognizable prodromal features (Neurotorium, 2026; Parkinson's Foundation). Constipation affects an estimated 60% or more of PD patients, and roughly a quarter of those report it began before any motor symptoms appeared (Chen et al., Scientific Reports, 2018). A 2024 study published in Gut (BMJ) found that constipation, dysphagia, gastroparesis, and irritable bowel syndrome without diarrhea may specifically predict the future development of PD.

This is not a coincidence. It is, increasingly, understood to be a clue about where the disease may begin.

2b. The Braak Hypothesis: Parkinson's May Start in the Gut

In 2003, the German neuropathologist Heiko Braak proposed a staging model for PD in which alpha-synuclein pathology (the misfolded protein aggregates that form Lewy bodies, the hallmark of PD) begins not in the brain, but in the enteric nervous system, the network of neurons lining the gastrointestinal tract. From there, Braak hypothesized, the misfolded proteins propagate upward through the vagus nerve to the brainstem and eventually to the substantia nigra.

The evidence supporting this hypothesis has grown substantially:

Post-mortem tissue studies have found alpha-synuclein aggregates in the gut wall of PD patients, including in samples taken years before motor diagnosis (Bloch et al., 2006; Braak et al., 2006; Shannon et al., 2012). Some studies have detected abnormal alpha-synuclein in gastric tissues up to 20 years before diagnosis (Neural Regeneration Research, 2025).

Animal studies have demonstrated direct propagation of Parkinson's pathology from gut to brain. When the pesticide rotenone was administered to the gastrointestinal tract of mice, it triggered alpha-synuclein accumulation that spread upward to the brainstem (Pan-Montojo et al., PLoS One, 2010). Severing the vagus nerve before rotenone administration stopped this spread.

Epidemiological evidence from vagotomy studies. Two large population-based studies (one Danish, one Swedish) examined people who had undergone vagotomy (surgical severing of the vagus nerve, once a common treatment for peptic ulcers). Both found that truncal vagotomy (which severs the main trunk of the vagus) was associated with a reduced risk of subsequent PD diagnosis, while selective vagotomy (which spares the main trunk) showed no such effect (Svensson et al., Annals of Neurology, 2015; Liu et al., Neurology, 2017). The Swedish study noted the risk reduction was strongest after 5 to 10 years of follow-up.

This does not mean Parkinson's always starts in the gut. The Braak model may describe one important subtype. A 2025 revision based on extensive post-mortem analysis suggests that alpha-synuclein pathology typically originates either in the olfactory bulb or in the peripheral nervous system (including the gut), but rarely both simultaneously (Springer, Journal of Neurology, 2025). Both a "bottom-up" and "top-down" etiology have been proposed, and the evidence suggests they are not mutually exclusive.

But the gut-first pathway is well enough supported that it is now central to PD research.

3. Dysbiosis: What's Happening in the Parkinson's Gut

The term "dysbiosis" refers to an imbalance in the composition of the gut microbiome, the trillions of bacteria that inhabit the intestinal tract. In PD, the dysbiotic pattern is now well-documented:

Decreased short-chain fatty acid (SCFA) producing bacteria. Bacteria in the families Lachnospiraceae and genera such as Faecalibacterium (a major butyrate producer) are consistently depleted in PD patients (Sustainable Microbiology, Oxford, 2026; Neurology, Chen et al., 2022). SCFAs, particularly butyrate, are critical for maintaining the integrity of the intestinal lining (the epithelial barrier) and for regulating inflammation. When these bacteria are depleted, the gut barrier weakens.

Increased LPS-producing (gram-negative) bacteria. With the decline of SCFA-producing species, there is a relative overgrowth of gram-negative bacteria that produce lipopolysaccharide (LPS), a potent inflammatory endotoxin.

A self-reinforcing cycle. Fewer SCFA-producing bacteria means less butyrate to maintain the gut lining. A weakened gut lining allows LPS and other bacterial products to leak into the bloodstream (a state sometimes called metabolic endotoxemia or "leaky gut"). Circulating LPS activates the immune system systemically, triggering chronic low-grade inflammation. This inflammation further damages the gut lining, further reduces beneficial bacteria, and the cycle continues.

A 2025 study in Scientific Reports (Nature) reported that in a randomized, double-blind trial of 72 PD patients, supplementation with short-chain fatty acids (propionic and butyric acid) and a prebiotic fiber over 6 months produced clinically meaningful improvements in motor symptoms. This is notable because it is an interventional trial, not just an association.

4. Endotoxemia: LPS and the Brain

The term "endotoxemia" refers to the presence of bacterial endotoxins (primarily LPS) in the bloodstream. A 2023 paper in Movement Disorders laid out what is now called "The Endotoxin Hypothesis of Parkinson's Disease" (Brown, Movement Disorders, 2023). The evidence includes:

• Gut dysfunction, permeability, and bacterial changes occur early in PD

• Serum levels of LPS are elevated in a proportion of PD patients

• LPS induces alpha-synuclein expression, aggregation, and neurotoxicity in experimental models

• LPS activates peripheral immune cells (monocytes), leading to production of inflammatory cytokines (TNF-alpha, IL-1beta, IL-6)

• Blood-borne LPS causes brain inflammation and specific loss of midbrain dopaminergic neurons in animal models, mediated by microglia (the brain's resident immune cells)

A 2025 study measuring circulating LPS-related biomarkers in PD patients found that elevated levels of LPS-binding protein (LBP), a marker of chronic low-grade endotoxemia, were associated with higher future risk of PD (International Journal of Molecular Sciences, PMC, 2025). Here is a similar 2026 paper.

In short: a compromised gut barrier allows bacterial toxins into the bloodstream, triggering systemic and brain inflammation that may directly contribute to the loss of dopaminergic neurons.

Alan Alda speaks about Parkinson's diagnosis

5. Mitochondrial Dysfunction: The Energy Crisis Inside the Cell

Alongside the gut-brain story, there is a parallel and converging line of evidence involving mitochondria, the organelles responsible for generating cellular energy (ATP).

The link between mitochondria and PD is among the oldest in the field. The first direct evidence came from the discovery that MPTP, a synthetic compound that specifically inhibits mitochondrial Complex I (the first step in the electron transport chain), causes a syndrome nearly identical to Parkinson's in humans and animals. Subsequent post-mortem studies confirmed that Complex I activity is significantly decreased in the substantia nigra of PD patients (Schapira et al., 1989; Parker et al., 1989).

Genetic evidence cemented the connection. Mutations in two genes, PINK1 and Parkin, cause autosomal recessive (inherited) early-onset Parkinson's. Both proteins are now known to be key regulators of mitophagy, the process by which cells identify and dispose of damaged mitochondria. When PINK1 or Parkin are dysfunctional, damaged mitochondria accumulate, generating excessive reactive oxygen species (ROS) and failing to produce adequate energy (Narendra and Youle, 2024; Frontiers in Aging Neuroscience, 2026). This provided the first direct evidence that mitochondrial dysfunction plays a primary, not secondary, role in PD development.

Dopaminergic neurons are especially vulnerable. The neurons lost in PD are among the most metabolically demanding in the brain. They have unusually long, highly branched axons and high baseline rates of oxidative metabolism. This makes them disproportionately dependent on healthy mitochondria and disproportionately susceptible to mitochondrial failure (Molecular Neurodegeneration, 2020).

The gut connection. LPS itself significantly induces mitochondrial damage. A 2021 review in International Journal of Molecular Sciences (PMC) found that LPS may contribute to PD pathology at least partially by inducing mitochondrial damage and aggravating apoptosis (cell death) in dopaminergic neurons. (Here is a similar paper from 2023.) This means gut dysbiosis and mitochondrial dysfunction are not separate problems; they can drive each other.

6. Nutritional Deficiencies and PD: What the Evidence Shows

Several nutritional factors are relevant both to the mechanisms described above and to PD specifically.

Glutathione

Glutathione (GSH) is the brain's primary intracellular antioxidant. Depleted neuronal GSH is one of the earliest measurable changes in the substantia nigra in PD (Riederer et al., 1989). People with PD have consistently lower glutathione levels in the brain regions affected by the disease. GSH is not well absorbed as an oral supplement; endogenous production depends on adequate cysteine, glycine, and glutamate, as well as cofactors including selenium and riboflavin. N-acetylcysteine (NAC), a cysteine donor, has shown preliminary promise. A small study in PD patients reported that oral NAC at 1,200 mg/day increased serum glutathione without adverse effects. A 2026 systematic review (Amino Acids, Springer) concluded that NAC shows promise as a neuroprotective intervention, but that evidence for both NAC and exogenous GSH remains preliminary and larger trials are needed.

Coenzyme Q10 (CoQ10)

CoQ10 is essential for mitochondrial electron transport and also acts as a lipid-soluble antioxidant protecting mitochondrial membranes. CoQ10 has been shown to be deficient in PD patients, particularly in the cerebellum. Six randomized controlled trials involving over 1,000 participants have investigated CoQ10 supplementation in PD with mixed results. An early trial by Shults et al. showed statistically significant slowing of functional decline at 1,200 mg/day, but the largest subsequent trial (QE3, 2014) did not confirm a benefit on the primary endpoint (Dietary supplements for Parkinson's disease, PMC, 2025). The evidence is inconclusive but the biological rationale remains strong, and CoQ10 supplementation at therapeutic doses is well-tolerated.

Omega-3 Fatty Acids (EPA/DHA)

Omega-3 polyunsaturated fatty acids, particularly DHA, are structural components of neuronal membranes. Emerging evidence suggests neuroprotective effects in PD through modulation of inflammation, oxidative stress, increased brain-derived neurotrophic factor (BDNF), and inhibition of apoptosis (Frontiers in Aging Neuroscience, 2014). Five RCTs have investigated omega-3 supplementation in PD, showing effects primarily on inflammatory and oxidative stress biomarkers rather than motor scores directly. One study showed that omega-3 supplementation reduced depression in PD patients (Da Silva et al., 2008).

For vegans and vegetarians: plant-based sources provide only alpha-linolenic acid (ALA), which has a low conversion rate to EPA and DHA (typically estimated at 5-10% for EPA, less than 5% for DHA). Vegans and vegetarians consistently show plasma DHA levels 0-40% lower than omnivores. Algae-derived DHA supplements are available and provide DHA directly without animal sources.

Vitamin B12

B12 is essential for myelin maintenance, neurotransmitter production, and methylation. Deficiency is common in long-term vegans and is associated with cognitive decline and neuropathy. In PD specifically, B12 status may be further compromised by levodopa therapy, which can increase homocysteine levels (a marker of methylation stress). B12 supplementation is straightforward and widely available in vegan-compatible forms (cyanocobalamin or methylcobalamin).

Vitamin D

Vitamin D deficiency has been associated with increased PD risk and worse disease severity in multiple observational studies. Vitamin D directly regulates mucosal immune function, including IgA class switching in the gut, connecting it to gut barrier integrity as well. Target levels of 60-80 ng/mL (25-OH-D) are often recommended in functional medicine contexts, typically requiring 5,000+ IU/day supplementation.

Fiber and Microbiome Diversity

Dietary fiber is the primary substrate for SCFA production by gut bacteria. Higher fiber intake and greater diversity of plant foods are consistently associated with greater microbial diversity and higher abundance of SCFA-producing species, including Faecalibacterium. A target of 30+ different plant foods per week has been shown to correlate with Faecalibacterium abundance, and 35-45 g/day of fiber from diverse sources is a commonly cited target. This is one area where a well-planned vegan or vegetarian diet may offer a genuine advantage.

7. What Does This Mean Practically?

This section is a summary of the domains where the evidence suggests there may be modifiable factors worth understanding and even exploring.

Gut health assessment. Comprehensive stool testing (e.g., GI-MAP or similar) can provide a snapshot of microbial composition, including levels of SCFA-producing bacteria, presence of opportunistic or pathogenic organisms, markers of intestinal inflammation (calprotectin), gut immune function (secretory IgA), and indicators of barrier integrity. This is not routinely ordered by neurologists but is available through functional medicine and integrative practitioners.

Nutritional testing. Panels such as the NutrEval (Genova Diagnostics) or similar functional nutrition profiles can identify deficiencies in glutathione precursors, CoQ10, B vitamins, omega-3 status, minerals, and markers of oxidative stress and mitochondrial function. Standard bloodwork can also be reviewed through a nutritional lens, looking at markers like homocysteine, methylmalonic acid (for functional B12 status), 25-OH-D, omega-3 index, hs-CRP, and ferritin.

Dietary patterns. A 2024 meta-analysis found that highest adherence to the Mediterranean diet was associated with a 25% reduction in PD risk (OR 0.75), with the association particularly strong for prodromal PD (OR 0.67) (Revue Neurologique, 2024). The MIND diet (a Mediterranean-DASH hybrid specifically designed for neurodegeneration) has shown similar associations. Both emphasize vegetables (especially leafy greens), berries, nuts, legumes, whole grains, and olive oil while minimizing ultra-processed foods and refined sugar. Both are compatible with a plant-based approach.

Fermented foods. Daily consumption of fermented foods (kimchi, sauerkraut, miso, tempeh, kombucha) has been shown to increase microbial diversity and reduce inflammatory markers. These are vegan-compatible.

Short-chain fatty acid support. Butyrate supplementation (as tributyrin, which survives upper GI transit better than sodium butyrate) is used in functional medicine to support gut barrier integrity while the underlying microbiome is being addressed. Prebiotic fibers that selectively feed butyrate-producing bacteria include inulin (chicory root, Jerusalem artichoke), arabinogalactan (larch), and pectin (apples, citrus).

Exercise. Though not the focus of this document, the evidence for exercise in PD is robust and worth noting. Exercise independently increases the abundance of Akkermansia and Faecalibacterium in clinical trials, reduces systemic inflammation, supports mitochondrial biogenesis, and improves both motor and non-motor PD symptoms. Current guidelines recommend 150+ minutes/week of moderate aerobic exercise plus resistance training 2-3 times/week.

8. The Big Picture

The research trajectory here is not fringe. The gut-brain axis in PD is now the subject of major review articles in Nature Reviews Gastroenterology & Hepatology, Movement Disorders, The Lancet (eClinicalMedicine), JAMA Neurology, Neurology, and Annals of Neurology. Mitochondrial dysfunction in PD is published in Nature, Cell, and Molecular Neurodegeneration. This is mainstream science, even if it has not yet fully filtered into standard clinical practice.

What this body of evidence suggests is that Parkinson's disease involves a systemic process, one in which the gut, the immune system, and cellular energy metabolism all participate, and in which nutritional status, dietary patterns, and microbial composition may be modifiable factors.

Key References

• Braak H et al. (2003). Staging of brain pathology related to sporadic Parkinson's disease. Neurobiology of Aging 24(2):197-211.

• Svensson E et al. (2015). Vagotomy and subsequent risk of Parkinson's disease. Annals of Neurology 78(4):522-529.

• Liu B et al. (2017). Vagotomy and Parkinson disease: A Swedish register-based matched-cohort study. Neurology 88(21):1996-2002.

• Brown GC (2024). The Endotoxin Hypothesis of Parkinson's Disease. Movement Disorders 39(7).

• Pereira et al. (2025). Supplementation with short-chain fatty acids and a prebiotic improves clinical outcome in Parkinson's disease. Scientific Reports 15.

• Menozzi E et al. (2025). The Gut-Brain Axis in Parkinson Disease: Emerging Concepts and Therapeutic Implications. Movement Disorders Clinical Practice.

• Multiple authors (2025). Gut-brain axis and environmental factors in Parkinson's disease. Neural Regeneration Research 20(12).

• Vos M (2022). Mitochondrial Complex I deficiency: guilty in Parkinson's disease. Signal Transduction and Targeted Therapy 7:136.

• Multiple authors (2026). Gut-brain axis dysregulation in Parkinson's disease. International Journal of Biological Macromolecules.

• Dietary supplements for Parkinson's disease: State of the science (2025). PMC.

• Impact of Vegan and Vegetarian Diets on Neurological Health: A Critical Review (2025). Nutrients 17(5):884.

Compiled September 2026. For informational purposes only.